Malin (MLLNF) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Malin Corporation PLC, an innovative life sciences investment firm, reports an intrinsic equity value of €6.44 per share as of June 2024, with a subsequent decrease to €6.33 by August, mainly due to a drop in Poseida’s share price and a weaker US Dollar. Following a lucrative divestment of CG Oncology shares, the company’s cash balance surged to €62.9 million, prompting a proposed €45 million capital return to shareholders via a tender offer slated for Q4 2024. This move is subject to shareholder and Irish High Court approvals, with an EGM called to discuss the necessary capital reduction.
For further insights into MLLNF stock, check out TipRanks’ Stock Analysis page.